TKD-005

TKD-005 is a thermostable vaccine candidate under development by Therakind, specifically designed for use in low- and middle-income countries (LMICs). The vaccine is formulated for intranasal administration, aiming to provide a needle-free delivery option that is easier to administer in resource-limited settings. A key feature of TKD-005 is its thermostability, which is intended to reduce or eliminate the reliance on stringent cold-chain logistics, a major barrier to vaccine distribution in many parts of the world. While the specific infectious disease target has not been publicly disclosed, the program leverages Therakind's expertise in stabilization and patient-centric drug delivery.